(Q34608783)

English

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

type 2 diabetes

0 references

0 references

cardiovascular disease

1 reference

based on heuristic

inferred from title

A Michael Lincoff

2

object named as

A Michael Lincoff

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Robert R Henry

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sunder Mudaliar

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Michael Rabbia

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Cathy Chognot

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Matthias Herz

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

8 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

374

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

9684

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

126-135

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

PPAR dual agonists: are they opening Pandora's Box?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(09)60870-9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34608783&oldid=1634884571"